August 13, 2024
ORLANDO, Florida — As increasing data show benefit for continuous glucose monitoring (CGM) devices beyond just insulin-treated diabetes, efforts are being made to optimize the use […]
May 29, 2024
TOPLINE: A low physical activity level combined with < 6 hours daily of sedentary time reduces the risk for all-cause and cardiovascular mortality in patients with […]
May 29, 2024
TOPLINE: The addition of bupropion/naltrexone to glucagon-like peptide 1 (GLP-1) receptor agonists leads to a further 4%-5% total body weight loss (TBWL) in patients with obesity, […]
May 28, 2024
BERLIN — What is the best way to help patients with diabetes, heart problems, and obesity lose weight and improve their outcomes? Is it exercise or […]
May 28, 2024
(Reuters) – As millions seek access to weight-loss drugs from Novo Nordisk and Eli Lilly, increasing supplies, possible wider usage and a growing number of would-be […]
May 27, 2024
TOPLINE: In women with gestational diabetes (GD), continuous glucose monitoring (CGM) shows elevated glycemic metrics earlier in pregnancy compared with the standard oral glucose tolerance test […]
May 25, 2024
In a 7 to 4 vote, an advisory panel to the US Food and Drug Administration (FDA) determined that the potential benefits of the investigational once-weekly […]
May 24, 2024
NEW ORLEANS — Medications in development would preserve muscle mass and augment fat loss when used in combination with glucagon-like peptide 1 (GLP-1) receptor agonists taken […]
May 23, 2024
DENVER — Postmenopausal women who receive hormone therapy show significantly greater weight loss when treated with the glucagon-like peptide 1 (GLP-1) receptor agonist drug semaglutide than […]